# In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline

> **NCT04468568** · — · COMPLETED · sponsor: **University of Sao Paulo General Hospital** · enrollment: 25 (actual)

## Conditions studied

- Myelomeningocele
- Terbutaline Adverse Reaction
- Pregnancy; Malformation Central Nervous System

## Interventions

- **DRUG:** Atosiban
- **DRUG:** Terbutaline

## Key facts

- **NCT ID:** NCT04468568
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2020-01-31
- **Final completion:** 2022-04-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04468568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04468568, "In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04468568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*